Recombinant Human Transmembrane protease serine 11B-like protein (TMPRSS11BNL)

What is the structural organization of TMPRSS11BNL and how does it compare to TMPRSS11B?

TMPRSS11BNL (Locus ID 401136, also known as FLJ41562) is a transmembrane serine protease structurally related to TMPRSS11B. While TMPRSS11B is well-characterized as containing one peptidase S1 domain and one SEA domain, TMPRSS11BNL maintains similar domain architecture but with sequence variations . Both proteins are single-pass type II membrane proteins belonging to the peptidase S1 family. The functional recombinant human TMPRSS11B protein spans from Leu39 to Leu416 in its mature form, with a calculated molecular weight of 43.1 kDa, though it typically appears at approximately 61 kDa in SDS-PAGE analysis due to post-translational modifications . The catalytic activity resides in the extracellular protease domain, which is anchored to a membrane-proximal cysteine through disulfide bonding, a feature common in DESC family proteases .

A critical distinction in experimental approaches involves recognizing that TMPRSS11BNL-targeting research tools must be specifically designed against its unique sequence variants, as indicated by its RefSeq designations (NM_001129907, NR_104048, NM_001129907.2) which differ from the canonical TMPRSS11B .

How is expression of TMPRSS11BNL/TMPRSS11B regulated in normal versus disease contexts?

TMPRSS11B expression demonstrates significant tissue-specific patterns, with notable upregulation in lung squamous cell carcinoma (LSCC) compared to normal lung tissue or other non-small cell lung cancer (NSCLC) subtypes including adenocarcinoma . Transcriptomic analyses reveal that high expression of TMPRSS11B correlates with poor survival outcomes in NSCLC patients, suggesting its potential utility as a prognostic biomarker .

Expression regulation appears to involve multiple mechanisms, including:

• Tissue-specific transcriptional programs active in squamous epithelial cells

• Potential dysregulation in cancer contexts, particularly in LSCC

• Possible involvement in host defense responses at mucosal surfaces

The physiological expression of TMPRSS11B in normal tissues appears predominantly restricted to epithelial surfaces, where it "may play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions" . This expression pattern differs significantly from the pathological upregulation observed in carcinoma contexts, suggesting differential regulatory mechanisms in normal versus disease states .

What are the optimal methods for expressing and purifying active recombinant TMPRSS11BNL for biochemical studies?

Successful expression of functional recombinant TMPRSS11B has been achieved using HEK293 cell expression systems, which facilitate proper folding and post-translational modifications essential for protease activity . For researchers designing experimental approaches to TMPRSS11BNL studies, the following methodology can be adapted:

Expression System Optimization:

• HEK293 cells provide superior yields of properly folded, active protein compared to bacterial expression systems

• Construct design should include the sequence from Leu39-Leu416 to ensure complete catalytic domain inclusion

• C-terminal His-tag facilitates purification while minimizing interference with N-terminal protease domain function

Purification Protocol:

• Culture transfected HEK293 cells in appropriate media for optimal protein expression

• Harvest conditioned media and/or prepare cell lysates (depending on secretion efficiency)

• Purify using immobilized metal affinity chromatography with appropriate buffering (20mM PB, 150mM NaCl, pH 7.4)

• Filter through 0.2 μm filtration system to ensure sterility

• Perform quality control via SDS-PAGE (expected MW ~61 kDa) and endotoxin testing (<1.0 EU per μg)

For biochemical assays, storing the purified protein at <-20°C with minimal freeze-thaw cycles maintains activity. When designing activity assays, researchers should note that TMPRSS11B's catalytic activity can be inhibited by serine protease inhibitors such as AEBSF (4-(2-aminoethyl)benzene-sulfonyl fluoride) .

What experimental approaches effectively evaluate TMPRSS11BNL/TMPRSS11B's role in cancer metabolic reprogramming?

Investigating TMPRSS11B's role in metabolic reprogramming requires a multifaceted approach combining genetic manipulation, metabolic profiling, and functional assays. Based on seminal research, the following experimental design framework is recommended:

Genetic Manipulation Strategies:

• Gain-of-Function: Stable ectopic expression of TMPRSS11B in appropriate cell models (e.g., HBECshp53 cells) using lentiviral delivery systems

• Loss-of-Function:

  • shRNA-mediated knockdown using validated constructs in high-expressing lines (e.g., HCC2814, H157)

  • CRISPR-mediated genome editing for complete knockout studies

  • Compare multiple targeting sequences to control for off-target effects

Metabolic Assessment Methods:

• Extracellular Acidification Rate (ECAR) measurement using Seahorse XF analyzer to assess glycolytic flux

• Lactate Export Quantification via enzymatic assays or metabolomics approaches

• Glucose Uptake Analysis using fluorescent glucose analogs (e.g., 2-NBDG)

When designing these experiments, researchers should include appropriate controls such as catalytically inactive TMPRSS11B mutants to distinguish between protease-dependent and independent effects .

How does TMPRSS11B interact with Basigin/MCT4 complex to enhance lactate export, and what experimental approaches can elucidate this mechanism?

TMPRSS11B modulates lactate metabolism through a novel mechanism involving proteolytic processing of Basigin (CD147), which functions as an obligate chaperone for the monocarboxylate transporter MCT4. Understanding this interaction requires specialized experimental approaches:

Mechanism Overview:
TMPRSS11B's extracellular protease domain catalyzes the solubilization of Basigin from the cell membrane, which enhances MCT4-mediated lactate export and promotes glycolytic metabolism in cancer cells . This represents a previously unrecognized regulatory mechanism for the Basigin/MCT4 complex.

Experimental Approaches to Investigate This Interaction:

• Soluble Basigin Quantification:

  • Collect conditioned media from TMPRSS11B-expressing versus control cells

  • Perform Western blot analysis with anti-Basigin antibodies to detect solubilized Basigin

  • Compare wild-type TMPRSS11B with catalytic mutants to confirm protease-dependent mechanism

• Protease Inhibition Studies:

  • Treat TMPRSS11B-expressing cells with the serine protease inhibitor AEBSF

  • Monitor dose-dependent reduction in Basigin solubilization

  • Establish concentration-response relationships for inhibition

• Genetic Dissection of Pathway Components:

  • Generate Basigin knockout cells using CRISPR/Cas9

  • Compare metabolic phenotypes between:

    • Control cells

    • TMPRSS11B-expressing cells

    • Basigin KO cells

    • TMPRSS11B-expressing Basigin KO cells

  • Validate findings through rescue experiments with CRISPR-resistant Basigin constructs

• Differential Contribution of MCT Transporters:

  • Distinguish between MCT1 and MCT4 contributions using:

    • MCT4 CRISPR knockout

    • Selective MCT1 inhibition with SR13800

  • Measure ECAR to quantify the relative importance of each transporter in TMPRSS11B-mediated metabolic effects

Analysis of these experiments reveals that TMPRSS11B proteolytic activity promotes approximately 10-fold enrichment in soluble Basigin levels in conditioned media. This solubilization enhances lactate export by the MCT4 transporter, with minimal contribution from MCT1, as evidenced by dramatic ECAR reduction in MCT4 KO cells but only minimal changes upon MCT1 inhibition .

What approaches can determine if TMPRSS11BNL influences tumor growth through mechanisms beyond metabolic reprogramming?

While metabolic effects of TMPRSS11B have been well-documented, comprehensive investigation of alternative mechanisms requires parallel experimental approaches:

Experimental Framework:

• Transcriptomic Profiling:

  • Perform RNA-seq comparing control versus TMPRSS11B-expressing/knockout cells

  • Analyze differential pathway enrichment beyond metabolism

  • Validate key targets by qRT-PCR and western blotting

• Substrate Identification:

  • Conduct proteomic screening of solubilized proteins in conditioned media

  • Implement TAILS (Terminal Amine Isotopic Labeling of Substrates) to identify direct proteolytic targets

  • Validate findings using in vitro cleavage assays with recombinant proteins

• Signaling Pathway Analysis:

  • Examine phosphorylation status of key oncogenic pathways

  • Determine if TMPRSS11B expression alters response to growth factors

  • Investigate potential receptor activation through proteolytic processing

• Tumor Microenvironment Studies:

  • Examine if TMPRSS11B affects extracellular matrix composition

  • Investigate potential immunomodulatory effects

  • Assess impact on angiogenesis and stromal cell recruitment

In xenograft models, TMPRSS11B inhibition through shRNA or CRISPR editing dramatically impairs tumorigenesis across multiple cancer cell types (HCC2814, H157, DU145), suggesting potential involvement in fundamental cancer-promoting processes beyond metabolism . The dramatic tumor growth impairment observed upon TMPRSS11B inhibition in these models indicates its potential as a therapeutic target.

How should researchers design loss-of-function studies to effectively evaluate TMPRSS11BNL's role in cellular processes?

Designing robust loss-of-function studies for TMPRSS11BNL requires careful consideration of targeting strategies, appropriate controls, and validation methods:

shRNA Approach Strategy:
When utilizing shRNA for TMPRSS11BNL knockdown, researchers should implement:

• Multiple independent shRNA constructs (minimum 4 unique 29mer shRNAs) targeting different regions of the transcript to control for off-target effects

• Scrambled shRNA controls in matching vector backbone (e.g., pGFP-C-shLenti)

• Quantitative assessment of knockdown efficiency via qRT-PCR and western blot

• Rescue experiments with shRNA-resistant constructs to confirm phenotype specificity

Available commercial shRNA kits (e.g., TL321236) provide multiple validated constructs targeting human TMPRSS11BNL (Locus ID 401136) in lentiviral vectors with GFP markers for tracking transduction efficiency .

CRISPR/Cas9 Gene Editing Approach:
For complete knockout studies:

• Design guide RNAs targeting early exons or essential catalytic domains

• Include non-targeting guide RNA controls

• Validate editing efficiency through:

  • Sequencing of targeted loci

  • Western blot confirmation of protein loss

  • Functional assays to confirm activity loss

• Generate multiple independent knockout clones to account for clonal variation

• Perform rescue experiments with wild-type protein to confirm specificity

Experimental Validation Protocol:

Researchers should note that TMPRSS11B inhibition shows consistent phenotypes across multiple cancer cell types, with xenograft experiments in immunocompromised NOD/SCID Il2rgγ-/- (NSG) mice demonstrating strong impairment of tumorigenesis following TMPRSS11B depletion .

What are the critical considerations when designing inhibition studies targeting TMPRSS11BNL protease activity?

Targeting TMPRSS11BNL/TMPRSS11B protease activity requires careful experimental design to ensure specificity and functional relevance:

Chemical Inhibition Approaches:

• Serine Protease Inhibitors:

  • AEBSF (4-(2-aminoethyl)benzene-sulfonyl fluoride) has demonstrated dose-dependent inhibition of TMPRSS11B-mediated Basigin solubilization

  • Implement dose-response studies (typically 0.1-1.0 mM range)

  • Include time-course analyses to determine optimal treatment duration

  • Monitor potential cytotoxicity at higher concentrations

• Structure-Based Inhibitor Design:

  • Utilize recombinant protein (e.g., His-tagged TMPRSS11B, Leu39-Leu416) for in vitro screening

  • Develop assays based on synthetic peptide substrates

  • Implement counterscreens against related proteases to ensure specificity

Genetic Catalytic Inactivation:

• Site-Directed Mutagenesis:

  • Generate catalytic triad mutants targeting the serine residue essential for protease activity

  • Compare wild-type TMPRSS11B with catalytically inactive mutants in functional assays

  • Validate loss of proteolytic activity using Basigin solubilization assay

Assessment of Inhibition Efficacy:

When designing inhibition studies, researchers should note that complete inactivation of TMPRSS11B through genetic approaches produces stronger phenotypes than partial inhibition through chemical means, suggesting that therapeutic strategies may require high-efficiency targeting to achieve clinical relevance .

How might TMPRSS11BNL's potential role in host defense systems inform new research avenues?

While TMPRSS11B has been primarily studied in cancer contexts, its physiological role in host defense systems presents compelling future research directions:

TMPRSS11B "may play some biological role in the host defense system on the mucous membrane independently of or in cooperation with other substances in airway mucous or bronchial secretions" . This function suggests several untapped research avenues:

• Epithelial Barrier Protection:

  • Investigate TMPRSS11BNL's role in maintaining mucosal barrier integrity

  • Examine potential interactions with antimicrobial peptides

  • Determine if TMPRSS11BNL processes defensins or cathelicidins to alter their activity

• Pathogen Interaction Studies:

  • Assess if TMPRSS11BNL processes viral surface proteins (similar to other airway proteases)

  • Investigate potential roles in bacterial colonization resistance

  • Examine expression changes during respiratory infections

• Inflammatory Response Modulation:

  • Determine if TMPRSS11BNL processes inflammatory mediators in the airway

  • Investigate its role in cytokine/chemokine activation or inactivation

  • Assess potential contribution to inflammatory lung diseases

• Comparative Biology Approaches:

  • Study evolutionary conservation across species with different respiratory exposures

  • Compare expression patterns in specialized respiratory epithelia

This unexplored aspect of TMPRSS11BNL biology may reveal connections between its physiological functions and pathological roles in cancer, potentially informing therapeutic strategies that selectively target disease-specific activities while preserving normal functions.

What emerging technologies could advance our understanding of TMPRSS11BNL biology and therapeutic targeting?

Several cutting-edge technologies and approaches could significantly accelerate TMPRSS11BNL research:

• Proteomics-Based Substrate Identification:

  • Implement advanced TAILS (Terminal Amine Isotopic Labeling of Substrates) proteomics

  • Apply proximity labeling approaches (BioID, APEX) to identify transient interaction partners

  • Develop activity-based protein profiling probes specific to TMPRSS11B

• Structural Biology Approaches:

  • Determine high-resolution structures of TMPRSS11BNL catalytic domain

  • Employ cryo-EM to visualize membrane-bound complexes with Basigin/MCT4

  • Utilize computational modeling to identify potential allosteric regulatory sites

• Single-Cell Technologies:

  • Apply scRNA-seq to map TMPRSS11BNL expression in heterogeneous tumors

  • Correlate expression with metabolic states at single-cell resolution

  • Implement spatial transcriptomics to locate TMPRSS11BNL-expressing cells within tumor architecture

• Novel Therapeutic Modalities:

  • Develop proteolysis-targeting chimeras (PROTACs) for TMPRSS11BNL degradation

  • Explore antibody-drug conjugates targeting the extracellular domain

  • Investigate mRNA-based approaches to modulate expression

• Combination Therapy Exploration:

  • Test synergy between TMPRSS11BNL inhibition and metabolic pathway targeting

  • Investigate potential synergistic effects with immunotherapy

  • Develop rational combination strategies based on synthetic lethality principles

The accessibility of TMPRSS11BNL's extracellular catalytic domain makes it particularly amenable to therapeutic targeting with biologics or small molecules, potentially enabling selective inhibition in cancer contexts while minimizing systemic toxicity .